Kamada Ltd. (KMDA)
| Market Cap | 261.27M |
| Revenue (ttm) | 124.86M |
| Net Income (ttm) | 14.61M |
| Shares Out | 44.75M |
| EPS (ttm) | 0.32 |
| PE Ratio | 17.85 |
| Forward PE | 44.05 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $5.73 |
| Previous Close | $5.67 |
| Change ($) | 0.06 |
| Change (%) | 1.06% |
| Day's Open | 5.63 |
| Day's Range | 5.55 - 5.75 |
| Day's Volume | 57,394 |
| 52-Week Range | 5.55 - 13.33 |
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
REHOVOT, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three months ended Marc...
On Wednesday, May 12, Kamada (NASDAQ:KMDA) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...
Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the interim ...
REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, single-...
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will prese...
Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the...
Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kamada (NASDAQ:KMDA) decreased 1.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 69.23% over the past year to $0.04, which missed...
REHOVOT, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months en...
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quar...
Transaction Represents Kamada's Entry into U.S. Plasma Collection Market and Advances the Company's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company
Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics
REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NA...
Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.
Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kamada (NASDAQ:KMDA) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 7.14% over the past year to $0.15, which beat the estimate of $0.06.
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quart...
We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a potential dis...
The biotech specializes in plasma-derived protein therapeutics.
REHOVOT, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has signed an agreement with the Israeli Ministr...
REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, ...
Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.
Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus study of it...
REHOVOT, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced the completion of enrollment and initial interim resu...
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s o...
REHOVOT, Israel and FORT LEE, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two leading biopharmaceutical companies specialized in plasma-derived pro...
Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call Transcript
Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Di...
Shares of Kamada (NASDAQ:KMDA) moved lower by 2.5% in pre-market trading after the company reported Q2 results.
REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months...
On Wednesday, August 12, Kamada (NASDAQ: KMDA) will release its latest earnings report.
REHOVOT, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that the first patient has been recruited to the Phase...
REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second qu...
Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.
Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
REHOVOT, Israel, June 17, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today provided an update on its development of a plasma-derive...
Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
About KMDA
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1990 |
| Stock Exchange NASDAQ | Ticker Symbol KMDA |
Financial Performance
In 2020, Kamada's revenue was $133.25 million, an increase of 4.76% compared to the previous year's $127.19 million. Earnings were $17.14 million, a decrease of -22.97%.
Analyst Forecasts
According to 3 analysts, the average rating for Kamada stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 91.97% from the latest price.